PMID- 11711685
OWN - NLM
STAT- MEDLINE
DCOM- 20020322
LR  - 20191105
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 12
IP  - 1
DP  - 2001 Sep
TI  - Thrombophilia and its treatment in pregnancy.
PG  - 23-30
AB  - Pulmonary embolism is the most common cause of maternal death during pregnancy 
      and the puerperium in the industrialized world. The risk of venous 
      thromboembolism (VTE) in pregnancy is 0.05%-1.8%, 6 times greater than in the 
      non-pregnant state. The risk is increased in women over 35 years and those with 
      obesity, previous VTE, operative delivery, or underlying thrombophilia. Women 
      presenting with recurrent miscarriages, preeclampsia, intrauterine growth 
      restriction, abruptio placentae, or stillbirth (all associated with microvascular 
      thrombosis in placental blood vessels) have high incidence (65%) of 
      thrombophilia. About 70% of the women who present with VTE during pregnancy are 
      carriers of hereditary or acquired thrombophilia. Treatment of women with VTE 
      during pregnancy, and especially those with thrombophilia, requires 
      individualized dosing and duration of antithrombotic therapy and the formulation 
      of thromboprophylactic strategies for future pregnancies. Warfarin is 
      contraindicated during the first trimester due to fetotoxicity; unfractionated 
      heparin (UFH) is associated with practical disadvantages and the risk of 
      heparin-induced thrombocytopenia (HIT) and osteoporosis with long-term use. Low 
      molecular weight heparins (LMWHs) are convenient to use, do not cross the 
      placenta, carry a lower risk of HIT and osteoporosis, and are safe and effective. 
      LMWHs are replacing UFH as the anticoagulant of choice during pregnancy and 
      improve pregnancy outcome in women with a history of obstetric complications and 
      confirmed thrombophilia.
FAU - Eldor, A
AU  - Eldor A
AD  - The Institute of Hematology, Tel-Aviv Sourasky Medical Center, The Sackler 
      Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. aeldor@post.tau.ac.il
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy/etiology
MH  - Thrombophilia/*drug therapy/etiology
MH  - Thrombosis/drug therapy/etiology/prevention & control
RF  - 77
EDAT- 2001/11/17 10:00
MHDA- 2002/03/23 10:01
CRDT- 2001/11/17 10:00
PHST- 2001/11/17 10:00 [pubmed]
PHST- 2002/03/23 10:01 [medline]
PHST- 2001/11/17 10:00 [entrez]
AID - 10.1023/a:1012730325902 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2001 Sep;12(1):23-30. doi: 10.1023/a:1012730325902.